Skip to main content
Study evaluates PET tracers in gauging Alzheimer's treatment efficacy
12/7/2017

Belgian researchers found that micro-PET with either F-18 FDG, F-18 florbetapir or F-18 PBR111 all identified pathologic differences between mouse models with Alzheimer's disease that received BACE1 inhibitor treatment and controls, but only F-18 florbetapir detected treatment-induced reduction of amyloid-beta pathology among those with Alzheimer's. The findings in the Journal of Nuclear Medicine "clearly showed that accurate quantification of amyloid-beta tracers is critically important and that the non-specific uptake in the brain of subjects might be underestimated for some existing Alzheimer's tracers that have fast metabolization profiles," researchers said.

Full Story: